dbACP: A Comprehensive Database of Anti-Cancer Peptides

25 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp02326 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption WST-1 assay 486P Bladder cancer IC50 : 251.47 µg/ml
dbacp02327 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption WST-1 assay RT4 Bladder cancer IC50 : 231.26 µg/ml
dbacp02328 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption WST-1 assay 647V Bladder cancer IC50 : 185.39 µg/ml
dbacp02329 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption WST-1 assay J82 Bladder cancer IC50 : 212.07 µg/ml
dbacp02330 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption Cell viability assay 486P Bladder cancer IC50 : 69.2 µg/ml
dbacp02331 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption Cell viability assay RT4 Bladder cancer IC50 : 96.22 µg/ml
dbacp02332 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption Cell viability assay 647V Bladder cancer IC50 : 28.74 µg/ml
dbacp02333 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption Cell viability assay J82 Bladder cancer IC50 : 99.01 µg/ml
dbacp02334 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption LDH leakage assay 486P Bladder cancer IC50 : 373.3/ µg/ml
dbacp02335 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption LDH leakage assay RT4 Bladder cancer IC50 : 289.3 µg/ml
dbacp02336 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption LDH leakage assay 647V Bladder cancer IC50 : 200.7 µg/ml
dbacp02337 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Silkmoth Membrane disruption LDH leakage assay J82 Bladder cancer IC50 : 319.2 µg/ml
dbacp02357 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay K-562 Leukemia cancer IC50 : 15.5 µM
dbacp02358 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay BTS-30 Breast cancer IC50 : 24.8 µM
dbacp02359 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay HRT-18 Colon cancer IC50 : 25.5 µM
dbacp02360 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay DLD-1 Colon cancer IC50 : >100 µM
dbacp02361 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay WEHI-3B Leukemia cancer IC50 : 4.4 µM
dbacp02362 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay A-2780 Ovarian cancer IC50 : 30.6 µM
dbacp02363 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay HCLO Colon cancer IC50 : 33.5 µM
dbacp02364 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay CHO-KI Ovarian cancer IC50 : 32 µM
dbacp02365 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay MAC15A Colon cancer IC50 : 37 µM
dbacp02366 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay MCF-7 Breast cancer IC50 : 42.5 µM
dbacp02367 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay HT-29 Colon cancer IC50 : >100 µM
dbacp02368 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay A-2780R Ovarian cancer IC50 : 34.5 µM
dbacp02369 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay MCF-7R Breast cancer IC50 : 24.5 µM